Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

CEL-SCI Corp (NYSE American:CVM)

1.85
Delayed Data
As of Nov 20
 -0.0485 / -2.55%
Today’s Change
1.46
Today|||52-Week Range
7.25
+10.21%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$22.5M

Company Description

CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Contact Information

CEL-SCI Corp.
8229 Boone Boulevard
Vienna Virginia 22182
P:(703) 506-9460
Investor Relations:

Employees

Shareholders

Other institutional9.80%
Individual stakeholders6.82%
Mutual fund holders1.64%

Top Executives

Geert R. KerstenCEO, CFO, Director & Chief Accounting Officer
Patricia B. PrichepSecretary & Senior Vice President-Operations
Eyal TalorChief Scientific Officer
William JonesVice President-Quality Assurance
Daniel H. ZimmermanSenior VP-Research & Cellular Immunology